<DOC>
	<DOCNO>NCT02564120</DOCNO>
	<brief_summary>NC ProCESS cohort patient diverse background diagnose early prostate cancer , enrol January 2011-June 2013 . These patient recruit throughout North Carolina , also partnership institution across country . Patients enrolled start treatment , follow prospectively treatment afterwards . This observational study collect information quality life , cancer control , health care receive inclusive treatment management subsequent effect include complication recurrence . The objective study examine comparative outcome among different modern prostate cancer treatment option cohort patient .</brief_summary>
	<brief_title>North Carolina Prostate Cancer Comparative Effectiveness &amp; Survivorship Study ( NC ProCESS )</brief_title>
	<detailed_description>Localized prostate cancer treatment option consistently `` high priority '' comparative effectiveness research ( CER ) topic accord Institute Medicine , Agency Healthcare Research Quality ( AHRQ ) , summary report . Patients urgently need information comparative outcome modern treatment option guide decision-making disease cause significant burden base high prevalence , mortality treatment effect quality life . The status quo pertains prostate cancer significant overtreatment cause potential patient harm , rapid diffusion new/expensive technology without proven benefit patient lack high quality research evidence balance direct-to-consumer advertising guide individualize decision-making . NC ProCESS population-based cohort design specifically address well-described knowledge gap . It design close collaboration unique AHRQ consortium stakeholder group , include representative patient , clinicians policymakers . Stakeholders help define study design emphasize `` real-world '' patient select patient-centered relevant outcome , involve throughout assembly patient cohort . The diverse cohort well-represented `` hard reach '' patient ; enrollment treatment avoids bias participation recall . As clinical trial feasible address central question prostate cancer CER , prospective study yield high level evidence inform patient stakeholder . With assembled cohort , study necessary examine comparative outcome .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Newlydiagnosed , histologicallyproven , localized prostate adenocarcinoma . Completion baseline interview prior initiate therapy . Patient ability complete study interview : cognitive impairment , language hearing problem . Not diagnosed prostate cancer transurethral resection prostate ( TURP ) . Age 3580 . English speaking . Has telephone . Initiation treatment prostate cancer prior completion baseline interview . Cognitive impairment . Hearing problem . Inability speak understand English .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>